Navigation Links
FDA Approves Test That Spots Aggressive Breast Cancer
Date:6/14/2011

TUESDAY, June 14 (HealthDay News) -- A new genetic test that helps determine if breast cancer patients are good candidates for treatment with the drug Herceptin was approved Tuesday by the U.S. Food and Drug Administration.

About 20 percent of breast cancers are HER2-positive, and respond well to Herceptin (trastuzumab).

The new Inform Dual ISH test reveals the number of copies of the HER2 gene in tumor tissue.

"When used with other clinical information and laboratory tests, this test can provide health-care professionals with additional insight on treatment decisions for patients with breast cancer," Alberto Gutierrez, director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health, said in an agency news release.

The FDA's approval of the test was based on a U.S. study that included tumor samples from 510 breast cancer patients. The study found that the test was effective in confirming a higher than normal number of copies of the HER2 gene in 96 percent of the HER2-positive tumor samples.

The test was also effective in excluding the possibility that more than the normal number of copies of the HER2 gene were present in 92.3 percent of HER2-negative tumor samples, according to the FDA.

Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said the new test will help "in acquiring the data about a woman's cancer more quickly and efficiently. This will help speed the process of formulating a treatment plan during a time when a woman is searching for answers regarding her future.

"The faster a treatment plan is formulated, the easier it is for a woman to deal with her diagnosis. When faced with too many unknowns, the diagnosis of breast cancer can be overwhelming. Because this test can be performed in a standard lab, the information regarding HER2 status will be known quickly, and a woman will know if her treatment will be over within a few months, or might go on for a full year," Bernick said.

Dr. Freya Schnabel, director of Breast Surgery at NYU Langone Medical Center, said: HER2 testing is an "important part of the assessment of breast cancer tissue, because it tells us important information about the biology of the tumor and also helps identify the subset of patients who would benefit from treatment with Herceptin. At this point, testing for HER2/neu frequently involves two levels of testing and there is sometimes lack of agreement between test results, making a patient's status unclear."

The new test is made by Tucson, Ariz.-based Ventana Medical Systems.

More information

The American Cancer Society has more about breast cancer.

-- Robert Preidt

SOURCES: Stephanie Bernik, M.D., chief of surgical oncology, Lenox Hill Hospital, New York City; Freya Schnabel, M.D., director of Breast Surgery, NYU Langone Medical Center, New York City; U.S. Food and Drug Administration, news release, June 14, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
2. The American Association of Anatomists approves guidelines for body donation programs
3. Golden Meditech Shareholders Approves of Name Change
4. New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals
5. Congress Approves Bill Curbing Internet Tobacco Sales in Victory for Kids and Taxpayers
6. House of Representatives Approves Health-Care Reform Bill
7. New York State Office of Mental Health Approves New High Performance Polycarbonate Sheet for Use in All Facilities
8. FDA Approves Stemedica IND for Ischemic Stroke Clinical Trial
9. FDA approves first human neural stem cell clinical trial to treat brain tumors
10. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
11. FDA approves Merz Pharmaceuticals Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Test That Spots Aggressive Breast Cancer
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware ... 3 kids do not brush their teeth the minimum two times a day that dentists ... with students missing 51 million hours of school and adults missing 164 million hours of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the perfect ... comes to maintaining good health. Every day, two kidneys filter about 120 to 150 ... of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Prima BioMed has presented encouraging early signs ... combination with Keytruda, with one of the six melanoma ... response. Recruitment in the second cohort is complete and ... by Q317. Preliminary efficacy data from the 15-patient, run-in ... mid-year (recruitment in the 226-patient Phase IIb component is ...
(Date:3/23/2017)... , March 23, 2017 ... consolidated vendor landscape with the top five players ... in 2015. These companies are Stryker Sustainability Solutions, ... Health Services, Inc., and VANGUARD AG. Despite the ... devices market is witnessing the prevalence of fierce ...
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
Breaking Medicine Technology: